1421703-82-3

Basic information

• Product Name: tert-butyl 4-((2-amino-4,5-dichlorophenyl)amino)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-((2-amino-4,5-dichlorophenyl)amino)piperidine-1-carboxylate
• CAS NO: 1421703-82-3
• Molecular Weight: 360.284
• Mol File: 1421703-82-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-((2-amino-4,5-dichlorophenyl)amino)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-((2-amino-4,5-dichlorophenyl)amino)piperidine-1-carboxylate(1421703-82-3)
• EPA Substance Registry System: tert-butyl 4-((2-amino-4,5-dichlorophenyl)amino)piperidine-1-carboxylate(1421703-82-3)

Safety Data

• Hazardous Substances Data: 1421703-82-3(Hazardous Substances Data)

Upstream product

• 5348-42-5 4,5-Dichloro-1,2-phenylenediamine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 2339-78-8 1,2-dichloro-4-fluoro-5-nitrobenzene 
• 1421703-70-9 tert-butyl 4-((4,5-dichloro-2-nitrophenyl)amino)piperidine-1-carboxylate 

Downstream Products

• 1421703-64-1 C₂₅H₃₁Cl₂N₅O 

Relevant articles and documents

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to 1,3,4-oxadiazole derivative compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutical composition comprising the same, a therapeutic method using the composition, and a method for preparing the same, and the 1,3,4-oxadiazole derivative compounds are represented by a following chemical formula (I).

SIGNALING-BIASED MU OPIOID RECEPTOR AGONISTS

The invention provides -opioid receptor agonists that are analgesic agents and that promote diminished side effects relative to a comparably effective dose of morphine. The side effects that are absent or attenuated include one or more of the following: constipation, respiratory depression, tolerance, dependence, nausea, confusion, sedation, hypotension, and post-treatment withdrawal symptoms.